| Literature identifier | Study type | Test dosage | Effective dosage | Endocrine-mediated endpoints | Systems-level perturbations |
|---|---|---|---|---|---|
| PMID:17904329 | IVR | 1000 mg/kg/day | 1000 mg/kg/day | Uterotrophic effect | Reproductive endocrine-mediated perturbations |
| PMID:21713527 | IVR | 10 mg/kg/day | - | No significant effects observed | - |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Atrophy of mammary gland | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Increase in T4 levels | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Decreased weights of accessory sex organs | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Changes in adrenal gland morphology | Metabolic endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Changes in haemocrit values | Immunological endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Changes in white blood cell (WBC) populations | Immunological endocrine-mediated perturbations | |
| IVR | 30 mg/kg/day | 30 mg/kg/day | Abnormal estrous cycles | Reproductive endocrine-mediated perturbations | |
| PMID:22504055 | IVR | 10 mg/kg/day | 10 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects the normal functioning of reproductive system | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Increased testis weights | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects cholesterol metabolism | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects steroidogenesis | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 200 mg/kg/day | 200 mg/kg/day | Affects steroid metabolism | Metabolic endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased FSH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Increased LH levels | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg/day | 50 mg/kg/day | Decreased cholesterol levels | Metabolic endocrine-mediated perturbations | |
| IVR | 2 mg/kg/day | - | No significant effects observed | - | |
| PMID:26435001 | IVTH | 0.000000001 - 0.00001 M | 0.0000001 - 0.00001 M | Cancer phenotype | Endocrine-mediated cancer |
| PMID:26751127 | IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decreased progestagens levels | Reproductive endocrine-mediated perturbations |
| IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decreased testosterone levels | Reproductive endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decrease in cortisol levels | Neurological endocrine-mediated perturbations | |
| IVTH | 0.00001 - 0.0005 M | 0.000001 - 0.00007 M | Decreased aldosterone levels | Metabolic endocrine-mediated perturbations | |
| PMID:27567155 | IVR | 100 mg/kg/day | 100 mg/kg/day | Increased testosterone levels | Reproductive endocrine-mediated perturbations |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Affects sexual behavior | Neurological endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 100 mg/kg/day | 100 mg/kg/day | Decreased inhibin-B levels | Reproductive endocrine-mediated perturbations | |
| PMID:28735473 | IVTH | 0.00001 M | 0.00001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations |
| IVTH | 0.00001 M | 0.00001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00000001 M | 0.00000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.00000001 M | 0.00000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Increased calcium levels | Metabolic endocrine-mediated perturbations | |
| PMID:30102602 | IVR | 0.05 mg/kg | 0.05 mg/kg | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations |
| IVR | 0.05 mg/kg | 0.05 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 0.5 mg/kg | 0.5 mg/kg | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Alters mammary gland development | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Changes in mammary gland morphology in offspring | Developmental endocrine-mediated perturbations;Reproductive endocrine-mediated perturbations | |
| PMID:30613871 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Affects cell metabolism | Metabolic endocrine-mediated perturbations |
| PMID:30823348 | IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Increased hepatic glycogen levels in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations;Metabolic endocrine-mediated perturbations |
| IVR | 0.1 mg/kg/day | 0.1 mg/kg/day | Oxidative stress in liver in offspring | Developmental endocrine-mediated perturbations;Hepatic endocrine-mediated perturbations | |
| PMID:31059536 | IVTH | 0.0000001 M | 0.0000001 M | Induce tumor progression | Endocrine-mediated cancer |
| IVTH | 0.0000001 M | 0.0000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000005 M | 0.000005 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000005 M | 0.000005 M | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.0000005 M | 0.0000005 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.0000005 M | 0.0000005 M | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Induce tumor progression | Endocrine-mediated cancer | |
| IVTH | 0.000001 M | 0.000001 M | Induced migration capability of tumor cells | Endocrine-mediated cancer | |
| PMID:31362132 | IVR | 50 mg/kg | 50 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations |
| IVR | 50 mg/kg | 50 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Oxidative stress in sperm | Reproductive endocrine-mediated perturbations | |
| IVR | 50 mg/kg | 50 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 20 mg/kg | 20 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects sperm motility | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Reduced sperm counts | Reproductive endocrine-mediated perturbations | |
| IVR | 5 mg/kg | 5 mg/kg | Affects fertility | Reproductive endocrine-mediated perturbations | |
| PMID:31388671 | IVTH | 0.000001 M | 0.000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
| IVTH | 0.000001 M | 0.000001 M | Cancer phenotype | Endocrine-mediated cancer | |
| PMID:31596606 | IVTH | 0.00000005 M | - | No significant effects observed | - |
| IVTH | 0.000005 M | - | No significant effects observed | - | |
| IVTH | 0.000000005 M | 0.000000005 M | Lead to obesity | Metabolic endocrine-mediated perturbations | |
| IVTH | 0.000000005 M | 0.000000005 M | Affects embryonic development | Developmental endocrine-mediated perturbations | |
| IVTH | 0.000000005 M | 0.000000005 M | Affects lipid metabolism | Metabolic endocrine-mediated perturbations | |
| PMID:9449681 | IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Occurrence of mammary gland tumor | Endocrine-mediated cancer;Reproductive endocrine-mediated perturbations |
| IVTH | 0.0000000001 - 0.00000001 M | 0.0000000001 - 0.00000001 M | Affects expression of progesterone receptor (PR) | Reproductive endocrine-mediated perturbations |
We have built a comprehensive resource which compiles potential endocrine disrupting chemicals (EDCs) based on the observed adverse effects or endocrine-mediated endpoints in published experiments on humans or rodents to support basic research. We are not responsible for any errors or omissions in the published research articles or supporting literature on potential EDCs compiled in this resource. Users are advised to exercise their own judgement on the weight of evidence for potential EDCs compiled in this resource. Importantly, our sole goal to build this resource on potential EDCs is to enable future basic research towards better understanding of the systems-level perturbations upon chemical exposure rather than influencing regulatory advice on chemical use.